NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance

In a phase IV trial, eighty-four patients (age 18–79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin-2 (IL-2) to prevent relapse in the post-consolidation phase. Aspects of natural killer (NK) cell biology were analyzed before and during immunotherapy with focus on outcome in older patients. In younger (<60 years old, n = 37) and older patients (>60 years old, n = 47), treatment with HDC/IL-2 resulted in an expansion of CD56bright and CD16+ NK cells in blood along with an increased NK cell expression of the natural cytotoxicity receptors (NCR) NKp30 and NKp46. In older patients, a high expression of NKp30 or NKp46 on CD16+ NK cells before and during therapy predicted leukemia-free and overall survival. These results suggest that NK cell functions determine relapse risk and survival in older AML patients and point to biomarkers of efficacy in protocols for remission maintenance.

[1]  D. Olive,et al.  Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. , 2002, Blood.

[2]  Sumati Rajagopalan,et al.  Controlling natural killer cell responses: integration of signals for activation and inhibition. , 2013, Annual review of immunology.

[3]  R. Biassoni,et al.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. , 2001, Annual review of immunology.

[4]  D. Gilliland,et al.  Drug therapy for acute myeloid leukemia. , 2005, Blood.

[5]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[6]  K. Hellstrand,et al.  Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. , 1994, Journal of immunology.

[7]  G. Juliusson,et al.  Acute myeloid leukemia in the real world: why population-based registries are needed. , 2012, Blood.

[8]  Marc Buyse,et al.  Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission , 2011, Haematologica.

[9]  J. Fischer,et al.  The role of KIR genes and ligands in leukemia surveillance , 2013, Front. Immun..

[10]  R. Foà,et al.  Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia , 2015, Oncoimmunology.

[11]  G. Trinchieri,et al.  Human natural killer cells. , 1979, Transplantation proceedings.

[12]  W. Hofmann,et al.  Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. , 2006, Blood.

[13]  Bob Löwenberg,et al.  Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Hills,et al.  Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Daniel Olive,et al.  Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. , 2007, Blood.

[16]  R. Biassoni,et al.  Human Natural Killer Receptors and Their Ligands , 2001, Current protocols in immunology.

[17]  A. Thiel,et al.  CD56brightCD16− Killer Ig-Like Receptor− NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation1 , 2007, The Journal of Immunology.

[18]  J. Aurelius,et al.  Immunotherapeutic strategies for relapse control in acute myeloid leukemia. , 2013, Blood reviews.

[19]  K. Rezvani,et al.  Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia , 2014, Haematologica.

[20]  A. Pera,et al.  Immunosenescence of Human Natural Killer Cells , 2011, Journal of Innate Immunity.

[21]  H. Kawasaki,et al.  Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. , 1996, Leukemia.

[22]  Lewis L Lanier,et al.  NK cell recognition. , 2005, Annual review of immunology.

[23]  K. Hellstrand,et al.  Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. , 1990, International archives of allergy and applied immunology.